Bortezomib

Bortezomib is a dipeptide boronic acid derivative that reversibly inhibits the 20S proteasome (Ki = 0.6 nM). It binds the beta5-subunit of the 20S proteasome and selectively inhibits chymotryptic activity. In part by blocking the degradation of tumor-suppressing and proapoptotic proteins, bortezomib drives cell cycle arrest and apoptosis in cancer cell lines and has applications in multiple myeloma and certain lymphomas, as well as other types of cancer. Proteasome inhibitors, including bortezomib, have potential in combination therapy with chemotherapy and radiation therapy against cancer.Formal Name: B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid. CAS Number: 179324-69-7. Synonyms: LDP-341, MG-341, MLN341, NSC 681239, PS-341. Molecular Formula: C19H25BN4O4. Formula Weight: 384.2. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 20 mg/ml, DMSO: 20 mg/ml, DMSO:PBS (pH 7.2)(1:5): 0.1 mg/ml. lambdamax: 269 nm. SMILES: O=C(N[C@@H](CC1=CC=CC=C1)C(N[C@H](B(O)O)CC(C)C)=O)C2=CN=CC=N2. InChi Code: InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1. InChi Key: GXJABQQUPOEUTA-RDJZCZTQSA-N.